Date: 2014-02-03
Type of information: Grant
Company: Galapagos (Belgium)
Investors: Flemish Agency for Innovation by Science and Technology (IWT) (Belgium)
Amount: €2.3 million
Funding type: grant
Planned used: This grant will support a 2-year project dedicated to the creation of a new research platform by integrating knowledge from a range of fibrotic diseases, including lung, kidney, liver, and skin fibrosis. This new platform will support Galapagos\' efforts to develop novel drug candidates in fibrosis.
Others: * On February 3, 2014, Galapagos has announced that it has been awarded a €2.3 million grant for research in fibrosis from the Flemish agency for Innovation by Science and Technology (IWT). The goal of this 2-year project is to create a new research platform by integrating knowledge from a range of fibrotic diseases, including lung, kidney, liver, and skin fibrosis. This new platform will support Galapagos\' efforts to develop novel drug candidates in fibrosis. Galapagos has a fully proprietary portfolio of fibrosis drug targets and molecules. The major aim of this IWT grant is to deliver a comprehensive fibrosis research platform, building on existing tools and considerable expertise within Galapagos and a number of academic laboratories. By integrating data obtained from pre-clinical and clinical research in several fibrotic diseases with similar root causes, Galapagos aims to create a unique fibrosis research environment, allowing for better selection of targets and molecules for the design of novel treatments in this area. Academic partners for the project include Prof Dr Wuyts (Pneumology, KU Leuven), Prof Dr Naesens and Prof Dr Kuypers (Nephrology, KU Leuven), Prof Dr Van Vlierberghe (Hepatology, U Ghent), Prof Dr F. De Keyser and Dr Smith (Scleroderma, U Gent) and Prof van Grunsven (Hepatology, VU Brussels).
Therapeutic area:
